| 词条 | Otamixaban |
| 释义 |
| Verifiedfields = changed | verifiedrevid = 462266309 | IUPAC_name = Methyl (2R,3R)-2- | image = Otamixaban.svg | image2 = Otamixaban 3D.png | tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = {{cascite|changed|??}} | CAS_number = 193153-04-7 | ATC_prefix = none | ATC_suffix = | PubChem = 5496659 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 4593439 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = S173RED00L | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 46618 | C=25 | H=26 | N=4 | O=4 | molecular_weight = 446.498 g/mol | smiles = O=C(OC)[C@H](Cc1cc(C(=[N@H])N)ccc1)[C@H](NC(=O)c3ccc(c2cc[n+]([O-])cc2)cc3)C | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C25H26N4O4/c1-16(22(25(31)33-2)15-17-4-3-5-21(14-17)23(26)27)28-24(30)20-8-6-18(7-9-20)19-10-12-29(32)13-11-19/h3-14,16,22H,15H2,1-2H3,(H3,26,27)(H,28,30)/t16-,22-/m1/s1 | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = PFGVNLZDWRZPJW-OPAMFIHVSA-N }}Otamixaban (INN) is an experimental injectable anticoagulant direct factor Xa inhibitor[1] that was investigated for the treatment for acute coronary syndrome. In 2013, Sanofi announced that it had ended development of the drug candidate after poor performance in a Phase III clinical trial.[2][3] References1. ^{{cite journal |vauthors=Guertin KR, Choi YM |title=The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development |journal=Curr. Med. Chem. |volume=14 |issue=23 |pages=2471–81 |year=2007 |pmid=17979700 |doi= 10.2174/092986707782023659|url=http://openurl.ingenta.com/content/nlm?genre=article&issn=0929-8673&volume=14&issue=23&spage=2471&aulast=Guertin}} {{Antithrombotics}}{{blood-drug-stub}}2. ^{{cite journal | journal = Chemical & Engineering News | publisher = American Chemical Society | date = June 10, 2013 | volume = 91 | number = 23 | page = 17 | title = AstraZeneca, Sanofi Cut Programs | quote = Sanofi is ending development on two compounds, the anticancer compound iniparib and the anticoagulant otamixaban, both of which flunked Phase III studies.}} 3. ^{{cite web|title=Sanofi's Investigational Iniparib, Otamixaban Fail To Meet Goals, Ends Programs|url=http://www.rttnews.com/2129222/sanofi-s-investigational-iniparib-otamixaban-fail-to-meet-goals-ends-programs.aspx|publisher=RTT news|accessdate=11 April 2014}} 1 : Anticoagulants |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。